Preliminary Results Of Real-Life Data Of Patients Implanted With Monofocal Plate Haptic Intraocular Lens

To evaluate the effectiveness and safety of the Acriva BB UDM 611 mono-focal plate haptic intraocular lens (VSY Biotechnology GmbH, Leinfelden-Echterdingen, Germany) according to real-life data of implanted patients.

A prospective observational study.

Patients who underwent phacoemulsification and intraocular lens (IOL) implantation due to cataracts were included in the study. The patient's preoperative and postoperative best-corrected visual acuity (BCVA) with logMAR, intraocular pressure, slit lamp biomicroscopic examination, optical or ultrasonographic biometry measurements, and endothelial count with a specular microscope were performed. Postoperative complications were recorded. Of the 299 patients included in the study, 13 were excluded due to preoperative posterior capsule rupture and lack of data. A total of 44 patients planned to be followed up for 12 months after surgery and whose third-month follow-up was completed were evaluated.

The mean age of the patients was 67.7±9.6 years. Three patients had glaucoma, four patients had age-related macular degeneration, and six patients had diabetic retinopathy. While the preoperative BCVA was 1.37±0.9, the postoperative 3rd-month BCVA was 0.16±0.31 (p<0.001). A total of 7 patients (15.9%) had posterior capsule opacity that did not require Nd YAG laser capsulotomy. IOL decentration or subluxation was not observed in any patient. Four patients with final visual acuity worse than 0.3 had a disciform scar in the macula, maculopathy, glaucomatous optic neuropathy and diabetic macular oedema.

Early results of Acriva BB UDM 611 mono-focal plate haptic lens implantation show that it is effective and safe. Long-term results will be known when the study is completed.